# Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct01373515/  
OnCo record `nct01373515` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Vididencel run by Mendus, completed.

## Summary

Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT01373515 by Mendus, with 12 participants enrolled, started 2011-04. Conditions recorded: Acute Myeloid Leukemia (AML) and Leukemic Dendritic Cell Vaccination. Interventions recorded: DCP-001.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01373515
- Phase: 1/2
- Setting: Phase 1 Study of Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia
- Sponsor: Mendus
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT01373515: https://clinicaltrials.gov/study/NCT01373515

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Vididencel](https://onco.cc/drugs/vididencel/)
- companies: [Mendus](https://onco.cc/companies/mendus/)

---
JSON: https://onco.cc/api/v1/entities/nct01373515.json